| US 7,455,846 B2 | ||
| Immune potentiating compositions of cancer cells | ||
| Stephen John Ralph, 9 Berwick Street, Brighton, Victoria, 3168 (Australia) | ||
| Assigned to Stephen John Ralph, Queensland (Australia) | ||
| Appl. No. 10/276,642 PCT Filed May 17, 2001, PCT No. PCT/AU01/00565 § 371(c)(1), (2), (4) Date Jun. 30, 2003, PCT Pub. No. WO01/88097, PCT Pub. Date Nov. 22, 2001. |
||
| Claims priority of application No. PQ7553 (AU), filed on May 17, 2000. | ||
| Prior Publication US 2004/0235156 A1, Nov. 25, 2004 | ||
| Int. Cl. A61K 39/00 (2006.01); C12N 5/00 (2006.01) | ||
| U.S. Cl. 424—277.1 [435/325] | 19 Claims |
| 1. A composition comprising:
a population of animal cancer cells that express a T cell co-stimulatory B-7 molecule selected from the group consisting of
B7-1 and B7-2 on the surface of said cells at a level at least 10-fold above a wild-type population of said cells, said cells
having been treated with a type II interferon (IFN) such that said cells have enhanced antigen presenting function relative
to animal cancer cells that have not been treated with a type II interferon (IFN); and
a type I IFN in isolated form.
|